Clinical trial
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
NCT06412497 is registered in ClinicalTrials.gov with Masonic Cancer Center, University of Minnesota as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- June 5, 2024
- Completion date
- May 1, 2036
- Enrollment
- 60 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
acquired amegakaryocytic thrombocytopenia, acquired pure red cell aplasia, paroxysmal nocturnal hemoglobinuria, severe aplastic anemia